Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

[Advanced Parkinson's disease: clinical characteristics and treatment (part 1)].

Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, Chacón J, García-Ruiz PJ, Lezcano E, Mir P, Martinez-Castrillo JC, Martínez-Torres I, Puente V, Sesar A, Valldeoriola-Serra F, Yañez R.

Neurologia. 2013 Oct;28(8):503-21. doi: 10.1016/j.nrl.2013.05.001. Epub 2013 Jul 13. Review. Spanish.

PMID:
23856182
[PubMed - indexed for MEDLINE]
Free Article
2.

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.

Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):718-27. doi: 10.1016/j.neurol.2008.11.017. Epub 2009 Jan 15. French.

PMID:
19150100
[PubMed - indexed for MEDLINE]
3.

Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA, Lanotte M, Rizzone MG, Lopiano L.

Brain. 2011 Jul;134(Pt 7):2074-84. doi: 10.1093/brain/awr121. Epub 2011 Jun 11.

PMID:
21666262
[PubMed - indexed for MEDLINE]
Free Article
4.

Neurostimulation for Parkinson's disease with early motor complications.

Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group.

N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158.

PMID:
23406026
[PubMed - indexed for MEDLINE]
Free Article
5.

Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Dodel RC, Berger K, Oertel WH.

Pharmacoeconomics. 2001;19(10):1013-38. Review.

PMID:
11735671
[PubMed - indexed for MEDLINE]
6.

Clinical predictive factors of subthalamic stimulation in Parkinson's disease.

Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y.

Brain. 2002 Mar;125(Pt 3):575-83.

PMID:
11872614
[PubMed - indexed for MEDLINE]
Free Article
7.

Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.

Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, Montanaro E, Reggio D, De Angelis C, Rizzone M, Lopiano L.

J Neurol. 2013 Jan;260(1):105-14. doi: 10.1007/s00415-012-6597-0. Epub 2012 Jul 8.

PMID:
22772358
[PubMed - indexed for MEDLINE]
8.

Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.

Pintor LP, Valldeoriola F, Fernández-Egea E, Sánchez R, Rami L, Tolosa E, Muñiz A, Martí MJ, Bernardo M.

J ECT. 2012 Jun;28(2):87-91. doi: 10.1097/YCT.0b013e31823c98c0.

PMID:
22531200
[PubMed - indexed for MEDLINE]
9.

Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.

Larsen JP, Karlsen K, Tandberg E.

Mov Disord. 2000 Sep;15(5):826-9.

PMID:
11009186
[PubMed - indexed for MEDLINE]
10.

Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.

Yamada K, Goto S, Hamasaki T, Kuratsu JI.

Acta Neurochir (Wien). 2008 Jan;150(1):15-22; discussion 22. doi: 10.1007/s00701-007-1451-3. Epub 2008 Jan 10.

PMID:
18180867
[PubMed - indexed for MEDLINE]
11.

Treatment of advanced Parkinson's disease.

Diamond A, Jankovic J.

Expert Rev Neurother. 2006 Aug;6(8):1181-97. Review.

PMID:
16893346
[PubMed - indexed for MEDLINE]
12.

[Levodopa in the treatment of Parkinson's disease: myths and realties].

Luquin MR, García-Ruiz PJ, Martí MJ, Rojo A, Vela L, Grandas FJ, Bravo-Utrera M, Burguera JA, Chacón JR, Campos-Arillo VM, Durán-Herrera C, Fernández-García JM, García-Ramos R, Gómez-Esteban JC, Gutierrez J, Juni J, Mata M, Martínez-Castrillo JC, Olivares J, Ribacoba-Montero R, Santos-García D, Sierra M, Valero-Merino C.

Rev Neurol. 2012 Dec 1;55(11):669-88. Review. Spanish.

PMID:
23172094
[PubMed - indexed for MEDLINE]
Free Article
13.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
[PubMed - indexed for MEDLINE]
14.

Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.

Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N.

Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):79-89.

PMID:
22338551
[PubMed - indexed for MEDLINE]
15.

Motor complications in Parkinson's disease: ten year follow-up study.

López IC, Ruiz PJ, Del Pozo SV, Bernardos VS.

Mov Disord. 2010 Dec 15;25(16):2735-9. doi: 10.1002/mds.23219.

PMID:
20931632
[PubMed - indexed for MEDLINE]
16.

Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.

PMID:
22283961
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.

Solla P, Cannas A, Floris GL, Orofino G, Costantino E, Boi A, Serra C, Marrosu MG, Marrosu F.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1009-13. doi: 10.1016/j.pnpbp.2011.02.002. Epub 2011 Feb 13.

PMID:
21324349
[PubMed - indexed for MEDLINE]
18.

The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.

Kostić VS, Marinković J, Svetel M, Stefanova E, Przedborski S.

Eur J Neurol. 2002 Jan;9(1):9-14.

PMID:
11784369
[PubMed - indexed for MEDLINE]
19.

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Parkinson Study Group.

JAMA. 2000 Oct 18;284(15):1931-8.

PMID:
11035889
[PubMed - indexed for MEDLINE]
20.

Motor complications in Parkinson disease: clinical manifestations and management.

Bhidayasiri R, Truong DD.

J Neurol Sci. 2008 Mar 15;266(1-2):204-15. Epub 2007 Sep 27. Review.

PMID:
17897677
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk